Adjuvant therapy of histopathological risk factors of
retinoblastoma in Europe: A survey by the European
Retinoblastoma Group (EURbG)

J 2021

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

DITTNER-MOORMANN, S., M. RESCHKE, F. C. H. ABBINK, I. AERTS, H. T. ATALAY et. al.

Basic information

Original name

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

Authors

DITTNER-MOORMANN, S., M. RESCHKE, F. C. H. ABBINK, I. AERTS, H. T. ATALAY, N. F. BOBROVA, E. BIEWALD, I. B. BRECHT, S. CASPI, N. CASSOUX, G. CASTELA, Y. DIARRA, C. DUNCAN, M. EBINGER, D. G. ALDANA, D. HADJISTILIANOU, Tomáš KEPÁK (203 Czech Republic, belonging to the institution), A. KLETT, H. KIRATLI, E. MAKA, E. OPOCHER, K. PAWINSKA-WASIKOWSKA, J. RASCON, I. RUSSO, O. RUTYNOWSKA-PRONICKA, C. S. ALVAREZ, S. S. PACHECO, K. SVOJGR, B. TIMMERMANN, V. VISHNEVSKIA-DAI, A. EGGERT, P. RITTER-SOVINZ, N. E. BECHRAKIS, H. JENKINSON, A. MOLL, F. L. MUNIER, M. B. POPOVIC, G. CHANTADA, F. DOZ and P. KETTELER (guarantor)

Edition

PEDIATRIC BLOOD & CANCER, HOBOKEN, WILEY, 2021, 1545-5009

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.838

RIV identification code

RIV/00216224:14110/21:00122125

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/pbc.28963

UT WoS

000628887900001

Keywords in English

biomarker; chemotherapy; childhood cancer; metastasis; radiotherapy; RB1 gene

Abstract

V originále

Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. Results Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.

Citovat

DITTNER-MOORMANN, S., M. RESCHKE, F. C. H. ABBINK, I. AERTS, H. T. ATALAY, N. F. BOBROVA, E. BIEWALD, I. B. BRECHT, S. CASPI, N. CASSOUX, G. CASTELA, Y. DIARRA, C. DUNCAN, M. EBINGER, D. G. ALDANA, D. HADJISTILIANOU, Tomáš KEPÁK, A. KLETT, H. KIRATLI, E. MAKA, E. OPOCHER, K. PAWINSKA-WASIKOWSKA, J. RASCON, I. RUSSO, O. RUTYNOWSKA-PRONICKA, C. S. ALVAREZ, S. S. PACHECO, K. SVOJGR, B. TIMMERMANN, V. VISHNEVSKIA-DAI, A. EGGERT, P. RITTER-SOVINZ, N. E. BECHRAKIS, H. JENKINSON, A. MOLL, F. L. MUNIER, M. B. POPOVIC, G. CHANTADA, F. DOZ and P. KETTELER. Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). PEDIATRIC BLOOD & CANCER. HOBOKEN: WILEY, 2021, vol. 68, No 6, p. 1-9. ISSN 1545-5009. Available from: https://dx.doi.org/10.1002/pbc.28963.

@article{1786843,
   author = {DittnerandMoormann, S. and Reschke, M. and Abbink, F. C. H. and Aerts, I. and Atalay, H. T. and Bobrova, N. F. and Biewald, E. and Brecht, I. B. and Caspi, S. and Cassoux, N. and Castela, G. and Diarra, Y. and Duncan, C. and Ebinger, M. and Aldana, D. G. and Hadjistilianou, D. and Kepák, Tomáš and Klett, A. and Kiratli, H. and Maka, E. and Opocher, E. and PawinskaandWasikowska, K. and Rascon, J. and Russo, I. and RutynowskaandPronicka, O. and Alvarez, C. S. and Pacheco, S. S. and Svojgr, K. and Timmermann, B. and VishnevskiaandDai, V. and Eggert, A. and RitterandSovinz, P. and Bechrakis, N. E. and Jenkinson, H. and Moll, A. and Munier, F. L. and Popovic, M. B. and Chantada, G. and Doz, F. and Ketteler, P.},
   article_location = {HOBOKEN},
   article_number = {6},
   doi = {http://dx.doi.org/10.1002/pbc.28963},
   keywords = {biomarker; chemotherapy; childhood cancer; metastasis; radiotherapy; RB1 gene},
   language = {eng},
   issn = {1545-5009},
   journal = {PEDIATRIC BLOOD & CANCER},
   title = {Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)},
   url = {https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.28963},
   volume = {68},
   year = {2021}
}

TY  - JOUR
ID  - 1786843
AU  - Dittner-Moormann, S. - Reschke, M. - Abbink, F. C. H. - Aerts, I. - Atalay, H. T. - Bobrova, N. F. - Biewald, E. - Brecht, I. B. - Caspi, S. - Cassoux, N. - Castela, G. - Diarra, Y. - Duncan, C. - Ebinger, M. - Aldana, D. G. - Hadjistilianou, D. - Kepák, Tomáš - Klett, A. - Kiratli, H. - Maka, E. - Opocher, E. - Pawinska-Wasikowska, K. - Rascon, J. - Russo, I. - Rutynowska-Pronicka, O. - Alvarez, C. S. - Pacheco, S. S. - Svojgr, K. - Timmermann, B. - Vishnevskia-Dai, V. - Eggert, A. - Ritter-Sovinz, P. - Bechrakis, N. E. - Jenkinson, H. - Moll, A. - Munier, F. L. - Popovic, M. B. - Chantada, G. - Doz, F. - Ketteler, P.
PY  - 2021
TI  - Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)
JF  - PEDIATRIC BLOOD & CANCER
VL  - 68
IS  - 6
SP  - 1-9
EP  - 1-9
PB  - WILEY
SN  - 15455009
KW  - biomarker
KW  - chemotherapy
KW  - childhood cancer
KW  - metastasis
KW  - radiotherapy
KW  - RB1 gene
UR  - https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.28963
N2  - Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. Results Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.
ER  -

DITTNER-MOORMANN, S., M. RESCHKE, F. C. H. ABBINK, I. AERTS, H. T. ATALAY, N. F. BOBROVA, E. BIEWALD, I. B. BRECHT, S. CASPI, N. CASSOUX, G. CASTELA, Y. DIARRA, C. DUNCAN, M. EBINGER, D. G. ALDANA, D. HADJISTILIANOU, Tomáš KEPÁK, A. KLETT, H. KIRATLI, E. MAKA, E. OPOCHER, K. PAWINSKA-WASIKOWSKA, J. RASCON, I. RUSSO, O. RUTYNOWSKA-PRONICKA, C. S. ALVAREZ, S. S. PACHECO, K. SVOJGR, B. TIMMERMANN, V. VISHNEVSKIA-DAI, A. EGGERT, P. RITTER-SOVINZ, N. E. BECHRAKIS, H. JENKINSON, A. MOLL, F. L. MUNIER, M. B. POPOVIC, G. CHANTADA, F. DOZ and P. KETTELER. Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). \textit{PEDIATRIC BLOOD \&{} CANCER}. HOBOKEN: WILEY, 2021, vol.~68, No~6, p.~1-9. ISSN~1545-5009. Available from: https://dx.doi.org/10.1002/pbc.28963.

Detailed Information on Publication Record